NCT/Study#

NCT02339571 /

EA6141

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase II/III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: